MorphoSys: Accelerating The Long Transformation
Executive Summary
Flush with funds from new partnering deals and recent capital injections, German biotech MorphoSys plans to boost its already considerable R&D spending to build value in the pipeline while holding on to promising assets longer.
You may also be interested in...
MorphoSys Hopes FDA Incentive Programs Can Boost Proprietary Plans
MorphoSys’s ambition to grow a proprietary pipeline got a boost with FDA giving its lead compound MOR208 fast track status for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Evotec Drug Development Strategy Offers Little Downside, Big Upside
Germany’s Evotec hopes to evolve into an integrated multi-service biopharma company through its three-pronged business strategy comprising a high-growth drug-discovery business, a series of pipeline options that pose no financial obligation for the biotech, and a growing list of scientific collaborations that offer potential long-term value.
Deal Watch: Hep C M&A Still Thriving; Plus AstraZeneca/Synairgen, MorphoSys/Merck Serono, ViiV/J&J
Merck beats out bids from AbbVie and Johnson & Johnson for Idenix Pharmaceuticals, gaining possession of three promising HCV drug candidates.